What is BellBrook Labs?
BellBrook Labs specializes in developing and supplying innovative biochemical assay solutions tailored for the intricate demands of drug discovery. Their core focus lies in enzyme drug targets, offering a comprehensive suite of high-throughput screening (HTS) assay kits, active enzymes, and bespoke assay development services. Serving a diverse clientele that includes major pharmaceutical corporations, agile biotech firms, and leading academic institutions, BellBrook Labs leverages over two decades of scientific expertise to deliver high-quality data and robust support. Their contributions are pivotal in advancing research across critical therapeutic areas such as oncology and autoimmune diseases, solidifying their position as a vital partner in the life sciences ecosystem.
How much funding has BellBrook Labs raised?
BellBrook Labs has raised a total of $137K across 1 funding round:
Debt
$137K
Debt (2021): $137K with participation from PPP
Key Investors in BellBrook Labs
PPP
Public-Private Partnership
What's next for BellBrook Labs?
The substantial capital infusion, particularly the recent strategic investment, positions BellBrook Labs for accelerated growth and expanded market penetration. This late-stage funding is indicative of strong investor confidence in the company's technology and its potential to significantly impact the drug discovery pipeline. Future endeavors will likely involve scaling operations, enhancing their product portfolio with cutting-edge assay technologies, and potentially forging new strategic partnerships to broaden their reach within the global pharmaceutical and biotechnology industries. The company's continued focus on enzyme kinetics and assay development suggests a trajectory aimed at becoming an indispensable resource for researchers seeking to expedite the identification and validation of novel therapeutic agents.
See full BellBrook Labs company page
